Inside information: Canatu Plc releases preliminary information on updated 2026 outlook and revenue for January-June 2026

Canatu Plc Inside Information 24 August 2026 at 11:15 a.m. EEST

Inside information: Canatu Plc releases preliminary information on updated 2026 outlook and revenue for January-June 2026

Canatu Plc (“Canatu”) announced today that it has received an order for a further CNT100 SEMI reactor from Korean semiconductor company FINE SEMITECH CORPORATION (FST). As noted in said release, while the order is expected to contribute to Canatu’s revenue already during the second half of 2026, the majority of the revenue generated from the order is expected to be recognized only in 2027.

Canatu will release its half-year financial report January-June 2026 on 25 August 2026. However, in connection with the disclosure of the reactor order, Canatu considers it important that the market simultaneously has access to a comprehensive and balanced view of the company's outlook for 2026. Accordingly, Canatu has decided to release the following preliminary information regarding its updated 2026 outlook, together with information regarding its revenue for the period January-June 2026 on which the updated outlook is based:

Updated 2026 outlook

Canatu continues to see strong long-term potential in its three business focus areas: Semiconductor, Robotics, Mobility and Defence, and Medical Diagnostics.

Canatu expects that its revenue for the financial year 2026 will decline significantly compared to the revenue of EUR 15.6 million in the financial year 2025.

In accordance with its disclosure policy, Canatu does not issue any specific numerical guidance for the financial year 2026.

• In the near term, Canatu sees that there are certain factors which affect the revenue visibility and continue to increase the volatility, in the Semiconductor and Robotics, Mobility and Defence businesses.
• Canatu has ongoing customer negotiations, the timing and outcome of which remain uncertain.
• The commercial roll-out of ready CNT pellicles, for example, ultimately depends on Canatu’s customers’ processes and timelines.
• The timeline for obtaining CNT100 SEMI reactor customer approvals is not fully within Canatu’s control, and the risk of delays cannot therefore be excluded.
• The approval of operating autonomous vehicles depends on regulations implemented by local governments.

Previous 2025 outlook published on 3 March 2026

Canatu continues to see strong long-term potential in its three business focus areas: Semiconductor, Automotive, and Medical Diagnostics.

In accordance with its disclosure policy, Canatu does not issue any specific numerical guidance for the financial year 2026.

• In the near term, Canatu sees that there are certain factors which affect the revenue visibility and continue to increase the volatility, in the Semiconductor and Automotive businesses.
• Canatu has ongoing customer negotiations, the timing and outcome of which remain uncertain.
• The commercial roll-out of ready CNT pellicles, for example, ultimately depends on Canatu’s customers’ processes and timelines.
• The timeline for obtaining the second CNT100 SEMI reactor customer approval (SAT) is not fully within Canatu’s control, and the risk of delays cannot therefore be excluded.

January-June 2026 revenue

As context for the updated outlook set out above, Canatu’s unaudited revenue for January-June 2026 amounted to EUR 4.2 million (H1 2025: EUR 7.3 million). The half-year financial report to be published on 25 August 2026 will include more detailed information on Canatu’s financial performance during the period.

Additional information

Mikko Vesterinen, CFO, mikko.vesterinen@canatu.com

Dr. Maximilian Slawinski, CEO, maximilian.slawinski@canatu.com

Certified adviser

DNB Carnegie Investment Bank AB (publ), tel. +46 (0) 8 588 685 70

About Canatu

Canatu (CANATU, Nasdaq First North, Finland) is a deep technology scaleup company creating advanced carbon nanotubes (Canatu CNTs), related products, and manufacturing equipment for the semiconductor, robotics, mobility and defense, and medical diagnostics industries. Canatu partners with forerunner companies, together transforming products for better tomorrows with nano carbon.

Canatu’s versatile platform technology has broad potential applications. Its current core includes CNT membranes for extreme ultraviolet (EUV) processes in the semiconductor industry, enabling more effective manufacturing of the most advanced chips. Additionally, electrochemical sensors for medical diagnostics are in the development phase. Canatu’s patented CNT reactors and Dry Deposition by Canatu^TM method yield clean and pristine CNTs. The company operates through two business models: selling CNT products directly, as well as selling CNT reactors and licensing the related technology so that customers can produce CNT products under a limited license.

Headquartered in Finland, Canatu also operates in the US, Japan and Taiwan. Founded in 2004 as a spin-off from Aalto University’s Nanomaterials Group, Canatu has 185 full-time equivalent employees representing over 35 nationalities, with nearly 20% holding or pursuing doctorates. Discover more at www.canatu.com and follow us on LinkedIn. 

Forward-looking statements

Certain statements in this release are “forward-looking statements”. Forward-looking statements include statements concerning plans, assumptions, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, the Company’s competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, its business strategy and the anticipated trends in the industry and the political and legal environment in which it operates and other information that is not historical information, such as revenue growth, EBIT growth, cost savings, investments, future cash flow generation, operating profit margin, operating capital expenditure, ratio of net debt and EBIT, revenue, and operating results. In some instances, they can be identified by the use of forward-looking terminology, including the terms “believes”, “intends”, “may”, “will” or “should” or, in each case, their negative or variations on comparable terminology.

Forward-looking statements in this company announcement are based on various assumptions, many of which in turn are based on assumptions. By their very nature, forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and the risk exists that the predictions, forecasts, projections, plans and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Any information, views and forward-looking statements contained in this company announcement speak only as at the date of this company announcement. Save as required by law, the Company or DNB Carnegie Investment Bank AB (publ) do not intend and do not assume any obligation to update or correct any forward-looking statement contained in this company announcement and do not undertake to publish such updates or corrections.